8 March 2021 in EP Europace
Vasovagal syncope (VVS) is the most common type of syncope and is usually considered a benign disorder. The potential for injury is worrisome but the likelihood is unknown. We aimed to determine the proportion of patients injured due to VVS. A systematic search of studies published until August 2020 was performed in multiple medical and nursing databases. Included studies had data on the proportion of patients with injury due to VVS prior to study enrolment. Random effects methods were used. Twenty-three studies having 3593 patients met inclusion criteria. Patients were diagnosed clinically with VVS, and 82% had >2 syncopal episodes before enrolment. Tilt test was positive in 60% and 14 studies reported comorbidities (32.6% hypertensive). The weighted mean injury rate was 33.5% [95% confidence interval (CI): 27.3–40.5%]. The likelihood of injury correlated with population age (r = 0.4, P = 0.05), but not with sex, positive tilt test, or hypertension. The injury rates were 25.7% (95% CI: 19.1–32.8%) in studies with younger patients (mean age ≤50 years, n = 1803) and 43.4% (95% CI: 34.9–52.3%) in studies with older patients (P = 0.002). Nine studies reported major injuries; with a weighted mean rate of major injuries of 13.9% (95% CI: 9.5–19.8%). Injuries due to syncope are frequent, occurring in 33% of patients with VVS. The risk of major injuries is substantial. Older patients are at higher risk. Clinicians should be aware of the risk of injuries when providing care and advice to patients with VVS.
25 July 2025 in International Journal of Cardiovascular Sciences
Anabolic-androgenic steroids (AAS) are a class of natural and synthetic hormones, which owe their name to their chemical structure (steroid nucleus) and their biological, anabolic, and androgenic effects. Misuse of AAS for aesthetic and performance purposes has become widespread, as they provide increases in muscle mass and strength. It is estimated that approximately 3.5% of the world’s population uses AAS. Use of AAS dates back to ancient Greece, followed by the Second World War. They were detected in sports competitions
8 April 2021 in Arquivos Brasileiros de Cardiologia
Physical activity and exercising are said to reduce the risk of cardiovascular mortality in the general population by 30%–50%, and mortality from any cause by 20%–50%. In cardiac patients, for each 1 Met increment (3.5 mL O2 kg−1 min−1) in functional capacity (FC) obtained in a cardiac rehabilitation program (CRP), we have a reduction in overall mortality of up to 13%., They reduce global hospitalization by 18%, and improve quality of life (QoL) in this population., After an angioplasty, CRP
16 April 2021 in International Journal of Cardiovascular Sciences
The disease caused by Coronavirus 2019 (COVID-19) is associated with significant mortality and morbidity, including pulmonary and cardiac adverse sequelae.1–3 It began in December 2019 in the city of Wuhan, and quickly became a pandemic, declared by the World Health Organization (WHO) on March 11 of 2019.4 By early September 2020, more than 28 million patients have been confirmed infected by COVID-19 in more than 200 countries.3 […] The Athlete’s Return in the Post-COVID-19 The disease caused by Coronavirus 2019 (COVID-19) is associated with significant mortality and morbidity, including pulmonary and cardiac adverse sequelae.1–3 It began in December 2019 in the city of Wuhan, and quickly became a pandemic, declared by the World Health Organization (WHO) on March 11 of 2019.4 By early September 2020, more than 28 million patients have been confirmed infected by COVID-19 in more than 200 countries.3 […] The Athlete’s Return in the Post-COVID-19
1 January 2025 in Arquivos Brasileiros de Cardiologia